Article Text

other Versions

PDF
Review
Evidence-based use of anti-TNFα therapy in Crohn's disease; where are we in 2011?
  1. S M Everett,
  2. P J Hamlin
  1. Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  1. Correspondence to Dr S M Everett, Leeds Teaching Hospitals NHS Trust, D Floor, Clarendon Wing, Leeds General Infirmary, Leeds LS1 3EX, UK; simon.everett{at}leedsth.nhs.uk

Abstract

The efficacy of anti-tumour necrosis factor (anti-TNFα) therapy with infliximab and adalimumab in moderate to severe Crohn's disease has now been proved. This article reviews the evidence supporting best practice with these agents in the light of recent National Institute for Health and Clinical Excellence guidance. Recent studies point to greater efficacy when these drugs are used early in the disease, particularly when mucosal healing can be achieved. For infliximab, the combination with immunomodulator drugs appears to afford greater efficacy, but possibly at the expense of the risk of rare but serious side effects. Patients should be selected carefully for treatment based on prognostic factors predicting aggressive disease, on the one hand, and comorbid factors that might predict side effects, on the other. Multiple drug combinations should be avoided where possible. Finally, a minority of patients in stable remission with complete mucosal healing may be selected for anti-TNFα drug withdrawal.

Statistics from Altmetric.com

Footnotes

  • Competing interests SME and PJH have both performed consultancy work and lecturing for Abbott and MSD (formerly Schering Plough).

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.